Infantile hemangioma (IH) is the most common vascular tumor of infancy occurring in 5%–10% of infants. The cause of IH onset has not been well elucidated, but IH has proven to be a disorder of angiogenesis and vasculogenesis with excessive proliferation of microvessels. Untreated IH will result in permanent changes leading to cosmetic dysfunction, and about 10% of IH are destructive and problematic with the increasing risk for disfigurement and functional impairment. Therefore, early medical management of IH is of vital importance to curb the rapid proliferation of IH. Although beta-adrenergic receptor blocker propranolol (PRN) has been widely used as the first-line therapy for IH because of its remarkable efficacy in treating proliferating IH since 2008, there are still concerns about the safety and resistance of PRN therapy for IH. Therefore, advances in the development of novel medical treatment for IHs and a better understanding of the molecular mechanisms about the action of the treatment are essential to improve the therapeutic efficacy of IH.
Currently, there are several issues about PRN therapy remain unsolved: (1) the low bioavailability and high-dose usage of PRN therapy in IH; (2) the potential long-term side effects of PRN in children; (3) resistance to PRN therapy in IH. To solve the above issue, many efforts have been made, including: (1) novel drug delivery technology to improve the bioavailability of PRN; (2) the application of alternative methods to PRN treatment; (3) advances in targeted therapies based on the deep understanding of the pathogenesis of IH. Nevertheless, future clinical trials and basic studies are needed to provide support to the above findings.
Therefore, for this Research Topic, we invite authors to submit Original Research, Reviews, and Clinical Trials that provide novel findings in the field of therapeutic approaches targeting IH. Topics of interest include:
• Clinical trials about beta-blocker therapy for IH
• Emerging drug therapies for IH
• Propranolol resistance and its molecular mechanism
• Effective drug delivery methods for IH
• Targeted therapy for IH
• Clinical findings about refractory IH
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Infantile hemangioma (IH) is the most common vascular tumor of infancy occurring in 5%–10% of infants. The cause of IH onset has not been well elucidated, but IH has proven to be a disorder of angiogenesis and vasculogenesis with excessive proliferation of microvessels. Untreated IH will result in permanent changes leading to cosmetic dysfunction, and about 10% of IH are destructive and problematic with the increasing risk for disfigurement and functional impairment. Therefore, early medical management of IH is of vital importance to curb the rapid proliferation of IH. Although beta-adrenergic receptor blocker propranolol (PRN) has been widely used as the first-line therapy for IH because of its remarkable efficacy in treating proliferating IH since 2008, there are still concerns about the safety and resistance of PRN therapy for IH. Therefore, advances in the development of novel medical treatment for IHs and a better understanding of the molecular mechanisms about the action of the treatment are essential to improve the therapeutic efficacy of IH.
Currently, there are several issues about PRN therapy remain unsolved: (1) the low bioavailability and high-dose usage of PRN therapy in IH; (2) the potential long-term side effects of PRN in children; (3) resistance to PRN therapy in IH. To solve the above issue, many efforts have been made, including: (1) novel drug delivery technology to improve the bioavailability of PRN; (2) the application of alternative methods to PRN treatment; (3) advances in targeted therapies based on the deep understanding of the pathogenesis of IH. Nevertheless, future clinical trials and basic studies are needed to provide support to the above findings.
Therefore, for this Research Topic, we invite authors to submit Original Research, Reviews, and Clinical Trials that provide novel findings in the field of therapeutic approaches targeting IH. Topics of interest include:
• Clinical trials about beta-blocker therapy for IH
• Emerging drug therapies for IH
• Propranolol resistance and its molecular mechanism
• Effective drug delivery methods for IH
• Targeted therapy for IH
• Clinical findings about refractory IH
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
